J. Marsden

发表

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

S. Whittaker, P. Tanière, C. Harwood, 2013, The British journal of dermatology.

Utility of adjuvant systemic therapy in melanoma

A. Hauschild, A. Eggermont, A. Testori, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

A. Hauschild, R. Dummer, A. Eggermont, 2008, The Lancet.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

M. Gore, P. Lorigan, N. Thatcher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.

J. Dunn, J. Marsden, A. Burton, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020 *

C. Proby, M. Mustapa, R. Mallipeddi, 2020, The British journal of dermatology.

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

M. Gore, C. Fisher, P. Hersey, 2020, Journal for ImmunoTherapy of Cancer.

prudent to ensure normal levels, and we feel that the wording of our article was appropriate.

J. Barrett, D. Bishop, D. Elder, 2010 .

Reply to P.E. Hutchinson et al

J. Barrett, D. Bishop, D. Elder, 2010 .

The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines.

M. Lens, V. Bataille, J. N. Bishop, 2007, Clinical medicine.

EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

A. Hauschild, R. Dummer, M. Gore, 2008 .

Melanoma erysipeloides: inflammatory metastatic melanoma of the skin

D. Sanders, J. Marsden, J. Marsden, 1993, The British journal of dermatology.

EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results

P. Ascierto, S. Aamdal, A. Eggermont, 2008 .

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

D. Schadendorf, R. Dummer, A. Testori, 2012, European journal of cancer.

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.

D. Schadendorf, R. Dummer, M. Gore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malignant melanoma of the gastro-intestinal tract: a case series.

T. Ismail, M. Thomson, K. Patel, 2014, International journal of surgery.

EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial

A. Hauschild, M. Gore, A. Eggermont, 2007 .

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (≥3 MM) or regional lymphnode metastasis (EORTC 18871)

E. Bröcker, U. Kleeberg, S. Suciu, 1999 .

Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma.

J. Barrett, D. Bishop, D. Elder, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant radiotherapy in patients with high‐risk cutaneous Squamous Cell Carcinoma After surgery (SCC‐AFTER): patient and carer views regarding a proposed clinical trial

R. Fitzpatrick, C. Jenkinson, C. Proby, 2022, Clinical and experimental dermatology.

A 10‐year review of surgical management of dermatofibrosarcoma protuberans *

C. Proby, R. Matin, A. Durack, 2020, The British journal of dermatology.

Dermatofibrosarcoma protuberans treated by micrographic surgery

D. Sanders, J. Marsden, R. Waters, 2002, British Journal of Cancer.

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

D. Schadendorf, A. Eggermont, D. Ruiter, 2004, European journal of cancer.

Revised UK guidelines for the management of cutaneous melanoma 2010.

M. Gore, P. Nathan, P. Lorigan, 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

D. Schadendorf, R. Dummer, A. Testori, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma

D. Bishop, M. Knowles, M. Harland, 2010, Genes, chromosomes & cancer.

Melanoma incidence in Australian commercial pilots, 2011–2016

A. Green, K. Karipidis, M. Coroneo, 2019, Occupational and Environmental Medicine.

Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.

K. Wheatley, Jayne S. Wilson, J. Marsden, 2016, Cancer treatment reviews.

Reply to response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45:76.

K. Wheatley, Jayne S. Wilson, J. Marsden, 2017, Cancer treatment reviews.

Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.

J. Larkin, P. Nathan, P. Lorigan, 2020, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Surgery and radiotherapy in the treatment of cutaneous melanoma

A. Hauschild, A. Eggermont, A. Testori, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Concerns regarding BRAF testing algorithm: reply from authors

S. Whittaker, P. Tanière, C. Harwood, 2013, The British journal of dermatology.

Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data.

J. Barrett, D. Bishop, I. D. S. Silva, 2009, European journal of cancer.

Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961.

P. Ascierto, S. Aamdal, A. Eggermont, 2010 .

Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma

J. Dunn, J. Marsden, A. Burton, 2001 .

Melanoma histopathology reporting: are we complying with the National Minimum Dataset?

J. Marsden, P. Colloby, M. Kaur, 2006, Journal of Clinical Pathology.

EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.

D. Schadendorf, R. Dummer, M. Gore, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

J. Larkin, P. Nathan, P. Lorigan, 2016 .

3 Adjuvant phase III trial (EORTC 18871) with RIFN-alpha 2B versus RIFNgamma versus Iscador versus observation for melanoma patients after surgery for high risk primary (>3 mm) or regional lymph node metastasis

A. Eggermont, E. Bröcker, U. Kleeberg, 2004 .

Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma

L. Billingham, L. Young, S. Berhane, 2011, Gene Therapy.

Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.

J. Jankowski, D. Sanders, J. Marsden, 1999, Molecular pathology : MP.

Palliation of skeletal melanoma metastases with isolated limb perfusion chemotherapy.

J. Marsden, D. Byrne, S. Rajpar, 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Environmental risk factors for relapse of melanoma☆

J. Barrett, D. Bishop, J. Newton-Bishop, 2008, European journal of cancer.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

P. Ascierto, S. Aamdal, L. Bastholt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vitamin D and survival from melanoma

J. A. Bishop, J. Barrett, T. Bishop, 2006 .

Does palpability of primary cutaneous melanoma predict dermal invasion?

D. Sanders, J. Marsden, B. O’Donnell, 1996, Journal of the American Academy of Dermatology.

Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.

M. Gore, P. Hersey, A. Dalgleish, 2014 .

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

L. Fearfield, E. Brown, J. Marsden, 2013, The British journal of dermatology.

D. Schadendorf, R. Dummer, M. Gore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

P. Ascierto, S. Aamdal, L. Bastholt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.